Table 1. Summary of clinical data.

Patients	Gender/Age (yrs)	Seizures	Duration of disease (days)	Seizure type	Tumor locationa	Diagnosis
P1	F/37	Yes	6	SGS	FT	II A
P2	M/30	Yes	4	SGS	F	II A
P3b	F/30	Yes	6	SGS	F	II A
P4	M/44	Yes	10	SGS	F	II A
P5	M/24	Yes	14	SGS	FT	II A
P6b	F/36	Yes	1	SGS	F	II A
P7	F/38	Yes	2	SGS	F	II A
P8	M/49	Yes	7	SGS	F	II A
P9	M/30	Yes	14	SGS	F	II A
P10	M/45	Yes	7	SGS	FT	II A
P11	M/31	Yes	7	SGS	F	II A
P12	F/40	No	1800	–	F	II A
P13	M/54	No	900	–	F	II A
P14b	M/37	No	600	–	F	II A
P15b	M/37	No	210	–	F	II A
P16	M/47	No	180	–	F	II A
P17	F/52	No	270	–	FT	II A
P18	M/21	No	259	–	F	II A
P19b	F/34	No	240	–	F	II A
P20	F/29	No	240	–	F	II A
P21	M/54	No	360	–	FT	II A
P22	M/18	No	360	–	F	II A
P23	M/47	No	570	–	F	II A

^aF, frontal; FT, frontal lobe with temporal involvement;

SGS, secondary generalized seizures;

II A, WHO grade II astrocytoma.

^bPCR samples used for internal validation.